Search Results for "entacapone"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for entacapone. Results 1 to 3 of 3 total matches.
See also: Comtan, Stalevo

Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
for this indication; tolcapone (Tasmar, and generics) and entacapone (Comtan, and generics) were approved earlier ...
The FDA has approved opicapone (Ongentys – Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an adjunct to carbidopa/levodopa in adults with Parkinson’s disease (PD) who experience "off" episodes. It is the third COMT inhibitor to be approved for this indication; tolcapone (Tasmar, and generics) and entacapone (Comtan, and generics) were approved earlier. Opicapone has been available in Europe since 2016.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):3-5 |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
Maintenance Dosage1 Cost2 COMT Inhibitors Entacapone – generic 200 mg tabs 200 mg PO tid or qid21 $190.80 ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
, diarrhea (worse with tolcapone), and urine discoloration can occur with entacapone and tolcapone ...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2021 Feb 22;63(1618):e1-9 |  Show IntroductionHide Introduction